Moreover, the 36-month beta value for CRSP is 1.60. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CRSP is 81.47M and currently, short sellers hold a 21.59% of that float. On November 05, 2024, CRSP’s average trading volume was 1.11M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CRSP) stock’s latest price update
CRISPR Therapeutics AG (NASDAQ: CRSP)’s stock price has gone decline by -4.64 in comparison to its previous close of 50.59, however, the company has experienced a -1.42% decrease in its stock price over the last five trading days. zacks.com reported 2024-11-05 that CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.41 per share a year ago.
CRSP’s Market Performance
CRISPR Therapeutics AG (CRSP) has experienced a -1.42% fall in stock performance for the past week, with a 6.06% rise in the past month, and a 2.06% rise in the past quarter. The volatility ratio for the week is 5.00%, and the volatility levels for the past 30 days are at 3.58% for CRSP. The simple moving average for the past 20 days is 0.49% for CRSP’s stock, with a -16.89% simple moving average for the past 200 days.
Analysts’ Opinion of CRSP
Many brokerage firms have already submitted their reports for CRSP stocks, with Needham repeating the rating for CRSP by listing it as a “Buy.” The predicted price for CRSP in the upcoming period, according to Needham is $84 based on the research report published on August 06, 2024 of the current year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $90. The rating they have provided for CRSP stocks is “Buy” according to the report published on August 02nd, 2024.
CRSP Trading at 2.23% from the 50-Day Moving Average
After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.04% of loss for the given period.
Volatility was left at 3.58%, however, over the last 30 days, the volatility rate increased by 5.00%, as shares surge +5.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.05% lower at present.
During the last 5 trading sessions, CRSP fell by -2.60%, which changed the moving average for the period of 200-days by -26.95% in comparison to the 20-day moving average, which settled at $47.98. In addition, CRISPR Therapeutics AG saw -22.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRSP starting from KASINGER JAMES R., who sale 1,089 shares at the price of $46.28 back on Oct 14 ’24. After this action, KASINGER JAMES R. now owns 62,597 shares of CRISPR Therapeutics AG, valued at $50,399 using the latest closing price.
Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 4,293 shares at $46.28 during a trade that took place back on Oct 14 ’24, which means that Kulkarni Samarth is holding 226,540 shares at $198,680 based on the most recent closing price.
Stock Fundamentals for CRSP
Current profitability levels for the company are sitting at:
- -1.65 for the present operating margin
- 0.31 for the gross margin
The net margin for CRISPR Therapeutics AG stands at -1.19. The total capital return value is set at -0.15. Equity return is now at value -14.00, with -11.72 for asset returns.
Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.83. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -18.68.
Currently, EBITDA for the company is -202.7 million with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of 20.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.73.
Conclusion
To wrap up, the performance of CRISPR Therapeutics AG (CRSP) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
